Technical Analysis for PTLA - Portola Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade B 26.84 4.80% 1.23
PTLA closed up 0.31 percent on Thursday, January 17, 2019, on 58 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical PTLA trend table...

Date Alert Name Type % Chg
Jan 17 Narrow Range Bar Range Contraction 4.80%
Jan 17 NR7 Range Contraction 4.80%
Jan 17 Inside Day Range Contraction 4.80%
Jan 17 Wide Bands Range Expansion 4.80%
Jan 17 Overbought Stochastic Strength 4.80%
Jan 17 Up 3 Days in a Row Strength 4.80%
Jan 17 Up 4 Days in a Row Strength 4.80%
Jan 17 Up 5 Days in a Row Strength 4.80%
Jan 16 Wide Bands Range Expansion 5.13%
Jan 16 Overbought Stochastic Strength 5.13%

Older signals for PTLA ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Portola Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of thrombosis, other hematologic disorders, and inflammation. Its development products include Betrixaban, an oral once-daily inhibitor of Factor Xa, which is in Phase III development trials for the treatment of venous thromboembolism prophylaxis in acute medically ill patients; and PRT4445, a recombinant protein that is in Phase II trials to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor who suffer an uncontrolled bleeding episode or undergo emergency surgery. The company's products under development also comprise PRT2070, which is in Phase I/II studies to treat B-cell hematologic cancers; and PRT2607 that is in Phase I clinical trials for inflammatory disorders. It has a license and collaboration agreement with Biogen Idec Inc. for the development and commercialization of its clinical-stage product candidates PRT2607; license and collaboration agreement with Aciex Therapeutics, Inc. to co-develop and co-commercialize PRT2070 and related compounds for nonsystemic indications; and an agreement with Astellas Pharma, Inc. to research, develop, and commercialize Syk inhibitors. The company was founded in 2003 and is headquartered in South San Francisco, California.
Is PTLA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 1 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 55.48
52 Week Low 14.81
Average Volume 1,943,062
200-Day Moving Average 30.0364
50-Day Moving Average 20.1576
20-Day Moving Average 20.208
10-Day Moving Average 23.329
Average True Range 1.4455
ADX 30.02
+DI 35.9548
-DI 10.7099
Chandelier Exit (Long, 3 ATRs ) 21.7735
Chandelier Exit (Short, 3 ATRs ) 19.1465
Upper Bollinger Band 27.1965
Lower Bollinger Band 13.2195
Percent B (%b) 0.89
BandWidth 69.165677
MACD Line 1.5923
MACD Signal Line 0.8267
MACD Histogram 0.7656
Fundamentals Value
Market Cap 1.48 Billion
Num Shares 57.6 Million
EPS -4.55
Price-to-Earnings (P/E) Ratio -5.63
Price-to-Sales 85.78
Price-to-Book 24.64
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 26.59
Resistance 3 (R3) 26.58 26.25 26.42
Resistance 2 (R2) 26.25 26.00 26.25 26.37
Resistance 1 (R1) 25.93 25.85 26.09 25.94 26.31
Pivot Point 25.60 25.60 25.68 25.60 25.60
Support 1 (S1) 25.28 25.35 25.44 25.29 24.91
Support 2 (S2) 24.95 25.20 24.95 24.85
Support 3 (S3) 24.63 24.95 24.80
Support 4 (S4) 24.64